<p>Zevin Asset Management LLC 在最近向證券交易委員會提交的 13F 表格中披露，其在諾華製藥 (NYSE:NVS - 免費報告) 的持股在第二季度減少了 2.1%。該公司在此期間出售了 2,173 股後，持有 99,336 股諾華的股票。諾華佔 Zevin Asset Management LLC 投資組合的 1.7%，是其第 24 大持股。根據其最近向證券交易委員會的申報，Zevin Asset Management LLC 在諾華的持股價值為 12,021,000 美元。</p>
<ul>
<li>諾華的月球計劃癌症療法可能成為未來的增長驅動力</li>
</ul>
<p>其他一些對沖基金和機構投資者也增加或減少了在 NVS 的持股。Brighton Jones LLC 在第四季度將其在諾華的持股增加了 76.5%。Brighton Jones LLC 目前持有 6,153 股諾華的股票，價值 599,000 美元，此前在此期間又購買了 2,666 股。Concurrent Investment Advisors LLC 在第一季度將其在諾華的持股增加了 39.9%。Concurrent Investment Advisors LLC 目前持有 5,795 股諾華的股票，價值 646,000 美元，此前在上一季度又購買了 1,652 股。Valeo Financial Advisors LLC 在第一季度將其在諾華的持股增加了 25.9%。Valeo Financial Advisors LLC 目前持有 8,520 股諾華的股票，價值 950,000 美元，此前在上一季度又收購了 1,755 股。Nisa Investment Advisors LLC 在第一季度將其在諾華的持股增加了 19.6%。Nisa Investment Advisors LLC 目前持有 1,222 股諾華的股票，價值 136,000 美元，此前在上一季度又收購了 200 股。最後，POM Investment Strategies LLC 在第一季度將其在諾華的持股增加了 1,275.0%。POM Investment Strategies LLC 目前持有 495 股諾華的股票，價值 55,000 美元，此前在上一季度又收購了 459 股。13.12% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>NVS 已成為多份分析師報告的主題。Weiss Ratings 在 10 月 31 日的研究報告中重申了對諾華股票的 &#34;買入 (b-)&#34; 評級。Jefferies Financial Group 在 10 月 27 日的研究報告中重申了對諾華股票的 &#34;持有&#34; 評級。HC Wainwright 在 10 月 27 日的研究報告中將諾華的評級下調至 &#34;中性&#34;。Cfra Research 在 10 月 29 日的研究報告中將諾華的評級上調至 &#34;持有&#34;。最後，摩根士丹利在 9 月 12 日的研究報告中重申了對諾華的 &#34;賣出&#34; 評級，並給出了 118.00 美元的目標價（之前為 119.00 美元）。一位股票研究分析師給予該股票 &#34;強烈買入&#34; 評級，三位給予 &#34;買入&#34; 評級，六位給予 &#34;持有&#34; 評級，三位給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，諾華目前的共識評級為 &#34;持有&#34;，共識目標價為 122.33 美元。</p>
<ul>
<li>三隻大型製藥股在美國投資超過 1000 億美元。</li>
</ul>
<p><strong>查看我們最新的諾華股票報告</strong></p>
<h2>諾華的價格表現</h2>
<p>諾華股票在週五開盤價為 126.49 美元。該公司的流動比率為 0.88，速動比率為 0.62，債務與股本比率為 0.50。該公司的市值為 2672 億美元，市盈率為 17.25，PEG 比率為 1.93，貝塔值為 0.60。諾華 AG 的 12 個月低點為 96.06 美元，12 個月高點為 133.55 美元。該公司的 50 日簡單移動平均線為 127.30 美元，200 日簡單移動平均線為 120.55 美元。</p>
<ul>
<li>三隻可能在市場波動後飆升的動量股</li>
</ul>
<p>諾華 (NYSE:NVS - 獲取免費報告) 最近在 10 月 28 日宣佈了其季度財報。該公司報告本季度每股收益 (EPS) 為 2.25 美元，低於分析師的共識預期 2.26 美元，差額為 0.01 美元。該公司本季度的收入為 139.1 億美元，而共識預期為 137 億美元。諾華的淨利潤率為 26.49%，股本回報率為 41.21%。該公司的收入同比增長 8.5%。在去年同期，該公司每股收益為 2.06 美元。賣方分析師預測諾華 AG 本年度將發佈 8.45 美元的每股收益。</p>
<h2>關於諾華</h2>
<p>(免費報告)</p>
<p>諾華 AG 從事醫療產品的研究、開發、生產和營銷，業務遍及瑞士及國際市場。該公司為患者和醫生提供處方藥。其專注於心血管、腎臟和代謝、免疫學、神經科學和腫瘤學等治療領域，以及眼科和血液學。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過諾華</li>
<li>投資汽車股票</li>
<li>防禦性投資：三隻報告強勁第三季度收益的分紅股票</li>
<li>如何投資 FAANG 股票</li>
<li>為什麼投資者不應害怕微軟股票的下跌</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>DigitalOcean 的潮流已轉變：準備迎接浪潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在諾華嗎？</h2>
<p>在考慮諾華之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而諾華並不在名單上。</p>
<p>雖然諾華製藥目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

諾華制藥

<p>Zevin Asset Management LLC 已將其在諾華製藥的持股比例減少了 2.1%，在第二季度出售了 2,173 股，剩餘持股為 99,336 股，價值約為 1200 萬美元。該公司將諾華列為其第 24 大持股。其他機構投資者也對諾華的持倉進行了調整。分析師對該股票的評級意見不一，普遍評級為 “持有”，目標價格為 122.33 美元。諾華最近報告每股收益為 2.25 美元，略低於預期，營收為 139.1 億美元，同比增長 8.5%</p>

<p>Zevin Asset Management LLC lowered its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 99,336 shares of the company's stock after selling 2,173 shares during the period. Novartis makes up 1.7% of Zevin Asset Management LLC's investment portfolio, making the stock its 24th biggest holding. Zevin Asset Management LLC's holdings in Novartis were worth $12,021,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Zevin Asset Management LLC 在最近向證券交易委員會提交的 13F 表格中披露，其在諾華製藥 (NYSE:NVS - 免費報告) 的持股在第二季度減少了 2.1%。該公司在此期間出售了 2,173 股後，持有 99,336 股諾華的股票。諾華佔 Zevin Asset Management LLC 投資組合的 1.7%，是其第 24 大持股。根據其最近向證券交易委員會的申報，Zevin Asset Management LLC 在諾華的持股價值為 12,021,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>諾華的月球計劃癌症療法可能成為未來的增長驅動力</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVS. Brighton Jones LLC raised its position in shares of Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after purchasing an additional 2,666 shares during the period. Concurrent Investment Advisors LLC grew its holdings in shares of Novartis by 39.9% during the first quarter. Concurrent Investment Advisors LLC now owns 5,795 shares of the company's stock valued at $646,000 after buying an additional 1,652 shares during the last quarter. Valeo Financial Advisors LLC increased its position in shares of Novartis by 25.9% during the first quarter. Valeo Financial Advisors LLC now owns 8,520 shares of the company's stock worth $950,000 after acquiring an additional 1,755 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Novartis by 19.6% during the first quarter. Nisa Investment Advisors LLC now owns 1,222 shares of the company's stock worth $136,000 after acquiring an additional 200 shares in the last quarter. Finally, POM Investment Strategies LLC raised its holdings in shares of Novartis by 1,275.0% in the 1st quarter. POM Investment Strategies LLC now owns 495 shares of the company's stock worth $55,000 after acquiring an additional 459 shares during the last quarter. 13.12% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者也增加或減少了在 NVS 的持股。Brighton Jones LLC 在第四季度將其在諾華的持股增加了 76.5%。Brighton Jones LLC 目前持有 6,153 股諾華的股票，價值 599,000 美元，此前在此期間又購買了 2,666 股。Concurrent Investment Advisors LLC 在第一季度將其在諾華的持股增加了 39.9%。Concurrent Investment Advisors LLC 目前持有 5,795 股諾華的股票，價值 646,000 美元，此前在上一季度又購買了 1,652 股。Valeo Financial Advisors LLC 在第一季度將其在諾華的持股增加了 25.9%。Valeo Financial Advisors LLC 目前持有 8,520 股諾華的股票，價值 950,000 美元，此前在上一季度又收購了 1,755 股。Nisa Investment Advisors LLC 在第一季度將其在諾華的持股增加了 19.6%。Nisa Investment Advisors LLC 目前持有 1,222 股諾華的股票，價值 136,000 美元，此前在上一季度又收購了 200 股。最後，POM Investment Strategies LLC 在第一季度將其在諾華的持股增加了 1,275.0%。POM Investment Strategies LLC 目前持有 495 股諾華的股票，價值 55,000 美元，此前在上一季度又收購了 459 股。13.12% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>NVS has been the subject of a number of analyst reports. Weiss Ratings reiterated a &#34;buy (b-)&#34; rating on shares of Novartis in a research note on Friday, October 31st. Jefferies Financial Group reaffirmed a &#34;hold&#34; rating on shares of Novartis in a research report on Monday, October 27th. HC Wainwright lowered Novartis to a &#34;neutral&#34; rating in a research report on Monday, October 27th. Cfra Research upgraded Novartis to a &#34;hold&#34; rating in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group reiterated a &#34;sell&#34; rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Novartis presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $122.33.</p>
<div class="lb-trans"><p>NVS 已成為多份分析師報告的主題。Weiss Ratings 在 10 月 31 日的研究報告中重申了對諾華股票的 &#34;買入 (b-)&#34; 評級。Jefferies Financial Group 在 10 月 27 日的研究報告中重申了對諾華股票的 &#34;持有&#34; 評級。HC Wainwright 在 10 月 27 日的研究報告中將諾華的評級下調至 &#34;中性&#34;。Cfra Research 在 10 月 29 日的研究報告中將諾華的評級上調至 &#34;持有&#34;。最後，摩根士丹利在 9 月 12 日的研究報告中重申了對諾華的 &#34;賣出&#34; 評級，並給出了 118.00 美元的目標價（之前為 119.00 美元）。一位股票研究分析師給予該股票 &#34;強烈買入&#34; 評級，三位給予 &#34;買入&#34; 評級，六位給予 &#34;持有&#34; 評級，三位給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，諾華目前的共識評級為 &#34;持有&#34;，共識目標價為 122.33 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻大型製藥股在美國投資超過 1000 億美元。</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on Novartis</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的諾華股票報告</strong></p>
</div><h2>Novartis Price Performance</h2>
<div class="lb-trans"><h2>諾華的價格表現</h2>
</div><p>Novartis stock opened at $126.49 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.50. The company has a market cap of $267.20 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.93 and a beta of 0.60. Novartis AG has a 12 month low of $96.06 and a 12 month high of $133.55. The business's 50 day simple moving average is $127.30 and its 200 day simple moving average is $120.55.</p>
<div class="lb-trans"><p>諾華股票在週五開盤價為 126.49 美元。該公司的流動比率為 0.88，速動比率為 0.62，債務與股本比率為 0.50。該公司的市值為 2672 億美元，市盈率為 17.25，PEG 比率為 1.93，貝塔值為 0.60。諾華 AG 的 12 個月低點為 96.06 美元，12 個月高點為 133.55 美元。該公司的 50 日簡單移動平均線為 127.30 美元，200 日簡單移動平均線為 120.55 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻可能在市場波動後飆升的動量股</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.26 by ($0.01). The firm had revenue of $13.91 billion during the quarter, compared to the consensus estimate of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. The company's revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.06 earnings per share. Sell-side analysts forecast that Novartis AG will post 8.45 EPS for the current year.</p>
<div class="lb-trans"><p>諾華 (NYSE:NVS - 獲取免費報告) 最近在 10 月 28 日宣佈了其季度財報。該公司報告本季度每股收益 (EPS) 為 2.25 美元，低於分析師的共識預期 2.26 美元，差額為 0.01 美元。該公司本季度的收入為 139.1 億美元，而共識預期為 137 億美元。諾華的淨利潤率為 26.49%，股本回報率為 41.21%。該公司的收入同比增長 8.5%。在去年同期，該公司每股收益為 2.06 美元。賣方分析師預測諾華 AG 本年度將發佈 8.45 美元的每股收益。</p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>關於諾華</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>諾華 AG 從事醫療產品的研究、開發、生產和營銷，業務遍及瑞士及國際市場。該公司為患者和醫生提供處方藥。其專注於心血管、腎臟和代謝、免疫學、神經科學和腫瘤學等治療領域，以及眼科和血液學。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Investing In Automotive Stocks</li>
<li>Getting Defensive: 3 Dividend Payers Reporting Strong Q3 Earnings</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Why Investors Shouldn’t Fear the Dip in Microsoft Stock</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過諾華</li>
<li>投資汽車股票</li>
<li>防禦性投資：三隻報告強勁第三季度收益的分紅股票</li>
<li>如何投資 FAANG 股票</li>
<li>為什麼投資者不應害怕微軟股票的下跌</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>DigitalOcean 的潮流已轉變：準備迎接浪潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在諾華嗎？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮諾華之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而諾華並不在名單上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然諾華製藥目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Zevin Asset Management LLC 出售了 2,173 股諾華製藥（Novartis AG）的股票，代碼為$NVS